Saturday 14 March 2026
  • About
  • Contact
  • Login
  • VC & Investment
  • M&A
  • AI
  • Podcasts
  • News
    • Pharmaceutical News
    • Biotechnology News
    • Generics News
    • Biosimilars news
    • In Brief
    • Legal
    • Company Pages
    • In The Boardroom
  • Insights
    • Analysis
    • Special Report
    • Interviews
    • Expert View
    • From Our Correspondent
    • One To Watch Companies
    • Digital Pharma
    • Pharma Leaders
  • Regulatory
    • FDA
    • EMA
    • Pricing, Reimbursement and Access
    • Regulation
    • Government Affairs
    • Biden Administration
  • Therapy Areas
    • Dermatologicals
    • Oncology
    • Neurological
    • Rare Diseases
    • Hematology
    • Cardio Vascular
    • Diabetes
    • Cell And Gene Therapy
  • Conferences
    • JPM Healthcare Conference
    • ESMO
    • ASCO
    • ASH
    • EULAR
    • AAIC
    • EASD
    • Conference News
  • Ones to Watch
  • About
  • Contact
  • Newsletter
  • Sign inSubscribe
Subscribe

Subscribe to our newsletters

The Pharma Letter offers free daily, weekly and monthly email alerts, providing a broad range of news insights and industry analysis direct to your inbox.

While the Daily Newsletter offers a roundup of all the headlines from the last 24 hours, the Weekly Roundup gives you our Editor's key insights into the leading pharma and biotech stories.

On a monthly basis, you can also stay abreast of key executive appointments with the Boardroom Bulletin, monitor emerging and rising biotech stars with the Start-ups and Scale ups Bulletin and keep an eye on all the dealmaking news with the M&A Bulletin.


Sign up to receive email updates

* indicates required
Newsletters

Today's issue

Immutep tanks as it discontinues ‘efti’ trial following futility analysis
Biotechnology
Immutep tanks as it discontinues ‘efti’ trial following futility analysis
13 March 2026
Pharmaceutical
Otsuka unveils new repinatrabit data in PKU
13 March 2026
Biotechnology
Purple Biotech’s CEO stepping down
13 March 2026
Pharmaceutical
Bayer in UK code breach over Eylea
13 March 2026
Biosimilars
3PBIOVIAN partners Colombia cancer institute on biosimilar
13 March 2026
Pharmaceutical
EMA outlines new AI and data roadmap for medicines regulation
13 March 2026
Pharmaceutical
Eli raises new funds to push radiopharma pipeline
13 March 2026


Company Spotlight

A Nasdaq-listed biopharmaceutical company developing small-molecule medicines for cardiovascular, metabolic and neurological diseases. Lexicon Pharmaceuticals focuses on therapies discovered through genetic and molecular research designed to address serious chronic conditions.

Latest Features

Biotechnology
Immutep tanks as it discontinues ‘efti’ trial following futility analysis
13 March 2026
Pharmaceutical
Otsuka unveils new repinatrabit data in PKU
13 March 2026
Biotechnology
Purple Biotech’s CEO stepping down
13 March 2026
Pharmaceutical
Bayer in UK code breach over Eylea
13 March 2026

The Pharma Letter

39-43 Putney High Street, Putney
London, SW15 1SP
United Kingdom


  • About us
  • Contact
  • Subscribe
  • Sponsorship/advertising
  • Company News Directory


  • Terms and Conditions
  • Privacy Policy
  • Twitter
  • Linkedin
Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze